May 8, 2017 / 11:47 AM / 10 months ago

BRIEF-Regeneron and Inovio enter immuno-oncology clinical study agreement

May 8 (Reuters) - Inovio Pharmaceuticals Inc:

* Regeneron and Inovio enter immuno-oncology clinical study agreement for glioblastoma combination therapy

* Regeneron Pharmaceuticals Inc - study will be conducted by inovio in patients with newly-diagnosed glioblastoma multiforme

* Regeneron-Study to evaluate co’s pd-1 inhibitor, regn2810, with Inovio’s ino-5401 t cell activating immunotherapy encoding multiple antigens and ino-9012

* Regeneron - trial will be solely conducted and funded by inovio, based upon a mutually agreed upon study design, and regeneron will supply regn2810

* Regeneron Pharmaceuticals Inc - Inovio and regeneron will jointly conduct immunological analyses in support of study

* Regeneron Pharmaceuticals Inc - Regeneron, in collaboration with Sanofi, is developing regn2810 both alone and in combination with other therapies Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below